A61P 35 - Antineoplastic agents

Patents for A61P 35 - Antineoplastic agents (221,099)
11/2002
11/06/2002	CN1378455A Use of diterpenoid triepoxides as anti-proliferative agent
11/06/2002	CN1378450A Novel class of cytodifferentiating agents and histone deactylase inhibitors, and methods of use thereof
11/06/2002	CN1378447A Use of cell membrane penetrating indigoid bisindole derivatives
11/06/2002	CN1378445A Drug releasing biodegradable fiber implant
11/06/2002	CN1378443A Cationic liposome delivery of taxanes to angiogenic blood vessels
11/06/2002	CN1377961A Ring structure ribo-enzyme and deoxy-ribozyme and their use
11/06/2002	CN1377894A Process for preparing egg yolk anti-cancer antibody and its use
11/06/2002	CN1377891A Zinc finger protein from dendritic cell, its coding sequence and use
11/06/2002	CN1377887A Polypeptide for inhibiting growth and migration of blood vessel endothelial cell and endothelial stem cell and its preparing method and use
11/06/2002	CN1377879A New alpha-amino acid sulfuryl compounds, its preparing method and medicinal composition containing them
11/06/2002	CN1377702A Lucid ganoderma wall-breaking spore powder capsule
11/06/2002	CN1377701A Traditional Chinese medicine preparation for curing cancer and preparing process
11/06/2002	CN1377694A Chinese patented medicine for preventing and curing cancer
11/06/2002	CN1377691A Medicine for curing tumor and preparing method
11/06/2002	CN1377648A Imiquimod or its derivative liposome for local skin and its preparing method and use
11/06/2002	CN1377647A 4-mercaptopyrrolidinyl derivative as fernesyl transferase inhibitor
11/06/2002	CN1377646A Anti-cancer medicine and its preparing method
11/06/2002	CN1377644A Anti-leukemia medicine
11/06/2002	CN1093852C 维生素ｄ酰胺衍生物 Amide derivatives of vitamin d
11/06/2002	CN1093767C Protein kinase C inhibitors
11/06/2002	CN1093766C Use of thexpahyrin in preparation of medicament for use with a chemotherapeutic agent in cancer chemosensitization
11/06/2002	CN1093763C Anti-cancer substance suppressing cancerous metastasis
11/05/2002	US6476264 N-(4-carbamimidoyl-phenyl)-glycine derivatives
11/05/2002	US6476209 Polynucleotides, materials incorporating them, and methods for using them
11/05/2002	US6476197 Polypeptides having interferon-γ inducing activity
11/05/2002	US6476195 Secreted protein HNFGF20
11/05/2002	US6476193 NLK1 protein and NLK1 protein complexes
11/05/2002	US6476079 Devices for the delivery of drugs having antiprogestinic properties
11/05/2002	US6476077 N-(2-phenyl-4-amino-butyl)-1-naphthamides as neurokinin-1 receptor antagonists
11/05/2002	US6476068 Platinum derivative pharmaceutical formulations
11/05/2002	US6476043 Use of camptothecin derivatives, with reduced gastrointestinal toxicity
11/05/2002	US6476040 Processes and intermediates for preparing anti-cancer compounds
11/05/2002	US6476026 Compounds and compositions as protease inhibitors
11/05/2002	US6476020 Imidazo-benzazepine compounds, their compositions and uses
11/05/2002	US6476018 Fused imidazole derivatives as multidrug resistance modulators
11/05/2002	US6476010 Orally administering to a post-menopausal woman a fat soluble vitamin and a fat soluble vitamin absorption increasing effective amount of l-carnitine or salts
11/05/2002	US6475996 Use of a vector expressing DNA polymerase β as medicine
11/05/2002	US6475986 Uses of THANK, a TNF homologue that activates apoptosis
11/05/2002	US6475783 Isolated nucleic acid molecule coding for tumor rejection antigen precursors MAGE-C1 and MAGE-C2 and uses thereof
11/05/2002	US6475766 Human osteoclast-derived cathepsin
11/05/2002	US6475644 Medical devices for delivery of targeted radioisotopes
11/05/2002	US6475487 Treatment of a patient by administering an antibody that inhibits cathepsin O
11/05/2002	US6475485 Two novel human cathepsin proteins
11/05/2002	US6475480 Use of adenoviral E4 reading frames to improve expression of a gene of interest
11/05/2002	US6475140 Flexible pressure resistant cover for the articulation system of a medical instrument
11/05/2002	CA2324467C Formulations for protection of peg-interferon alpha conjugates
11/05/2002	CA2205366C Meso-monoiodo-substituted tetramacrocyclic compounds and methods for making and using the same
11/05/2002	CA2109322C Bombesin analogs
11/05/2002	CA2038029C 1-alkyl-, 1-alkenyl- and 1-alkynylaryl-2-amino-1,3-propanediols and related compounds, a process and intermediates for their preparation and theeir use as medicaments
10/2002
10/31/2002	WO2002086443A2 Methods of diagnosis of lung cancer, compositions and methods of screening for modulators of lung cancer
10/31/2002	WO2002086156A2 New polynucleotides and polypeptides of the ifn$g(a)-17 gene
10/31/2002	WO2002086105A1 Delivery of polynucleotide agents to the central nervous sysstem
10/31/2002	WO2002086087A2 Cytokine protein family
10/31/2002	WO2002086085A2 Human timp-1 antibodies
10/31/2002	WO2002086078A2 Synthesis and evaluation of novel phthalimide mimics as anti-angiogenic agents
10/31/2002	WO2002086069A2 Secreted proteins
10/31/2002	WO2002085945A2 Vhh single heavy chain antibody and a method for its preparation in a mammal
10/31/2002	WO2002085944A2 Single chain camelid vhh antibodies, method for their production in a mammal and their uses
10/31/2002	WO2002085940A2 New polynucleotides and polypeptides of the erythropoietin gene
10/31/2002	WO2002085925A2 Melanocortin receptor ligands
10/31/2002	WO2002085905A1 Novel adenine derivatives
10/31/2002	WO2002085899A1 Heterocyclyldicarbamides as caspase inhibitors
10/31/2002	WO2002085897A1 Heterocyclic compounds for aging-related and diabetic vascular complications
10/31/2002	WO2002085895A1 Quinazoline derivatives
10/31/2002	WO2002085888A1 Tetrahydropyridyl-alkyl-heterocycles, method for preparing same and pharmaceutical compositions containing same
10/31/2002	WO2002085883A1 Tricyclic alkylhydroxamates, their preparation and their use as cell proliferation inhibitors
10/31/2002	WO2002085879A1 Three-step conversion of protected taxane ester to paclitaxel
10/31/2002	WO2002085878A1 Two-step conversion of protected taxane ester to paclitaxel
10/31/2002	WO2002085868A1 Benzoxazinone derivatives for use in the treatment of angiogenesis
10/31/2002	WO2002085859A1 HETEROARYL UREAS CONTAINING NITROGEN HETERO-ATOMS AS p38 KINASE INHIBITORS
10/31/2002	WO2002085857A2 Inhibition of raf kinase using quinolyl, isoquinolyl or pyridyl ureas
10/31/2002	WO2002085855A1 2-iminopyrrolidine derivatives
10/31/2002	WO2002085850A1 Cyclic amidine derivative
10/31/2002	WO2002085848A2 Synthesis of pancratistatin prodrugs
10/31/2002	WO2002085843A2 Process for the preparation of 1,3-substituted indenes and aryl-fused azapolycyclic compounds
10/31/2002	WO2002085459A2 Antiangiogenic combination therapy for the treatment of cancer
10/31/2002	WO2002085414A2 Nsaid formulations comprising lecithin oils for protecting the gastrointestinal tract and providing enhanced therapeutic activity
10/31/2002	WO2002085410A2 Method for evaluating the efficacy of treatment with bacterial dna and bacterial cell walls
10/31/2002	WO2002085409A2 Methods and compositions for inducing an immune response to an antigen
10/31/2002	WO2002085405A2 COMBINATION THERAPY USING ANTI-ANGIOGENIC AGENTS AND TNF$g(a)
10/31/2002	WO2002085399A1 Peptide-containing preparations
10/31/2002	WO2002085387A2 A medicament or a dressing containing a metal such as silver, gold, platinum or palladium as an antimicrobial agent ans their use in the treatment of inflammatory skin conditions
10/31/2002	WO2002085386A2 Medicament containing a metal such as silver, gold, platinum or palladium as an antimicrobial agent and their use to induce apoptosis in cancerous tissue
10/31/2002	WO2002085385A2 Medicament containing a metal such as silver, gold, platinum or palladium as an antimicrobial agent and their use in the treatment of diseases of the mucosa
10/31/2002	WO2002085384A2 Lubricious coatings for substrates
10/31/2002	WO2002085364A1 Farnesyl protein transferase inhibitors for treating cachexia
10/31/2002	WO2002085351A1 Favorable modulation of health-related quality of life and health-related quality-adjusted time-to-progression of disease in patients with prostate cancer
10/31/2002	WO2002085346A1 Use of creatine for the amelioration of oxidative stress
10/31/2002	WO2002085342A2 Use of nsaids for prevention and treatment of cellular abnormalities of the lung or bronchial pathway
10/31/2002	WO2002085340A2 Oligonucleotide compositions and their use to induce differentiation of cells
10/31/2002	WO2002085330A1 Biofunctional hydroxyapatite coatings and microspheres for in-situ drug encapsulation
10/31/2002	WO2002085327A2 Use of nsaids for prevention and treatment of cellular abnormalities of the female reproductive tract
10/31/2002	WO2002085311A2 Hcg formulation
10/31/2002	WO2002085309A2 Composition, formulations & kits for treatment of respiratory & lung disease with anti-sense oligonucleotides & a bronchodilating agent
10/31/2002	WO2002085308A2 Antisense and anti-inflammatory based compositions to treat respiratory disorders
10/31/2002	WO2002085305A2 Compositions and methods for inducing cancer cell death
10/31/2002	WO2002085299A2 Therapeutic treatments using the direct application of antimicrobial metal compositions
10/31/2002	WO2002085296A2 Composition, formulations and kit for treatment of respiratory and lung disease with non-glucocorticoid steroids and/or ubiquinone and a bronchodilating agent
10/31/2002	WO2002085286A2 Methods of using secondary lymphoid organ chemokine to modulate physiological processes in mammals
10/31/2002	WO2002068585A3 Tip39 polypeptides

1 ... 1644 1645 1646 1647 1648 1649 1650 1651 1652 1653 1654 1655 1656 1657 1658 1659 1660 1661 1662 1663 1664 ... 2211